Liver manifestation associated with covid-19 (Literature review)

IF 0.1 Q4 PERIPHERAL VASCULAR DISEASE

Revista Latinoamericana De Hipertension Pub Date : 2021-01-01 DOI:10.5281/zenodo.5110307

S. A. Joya, K. G. Medeubaevna, S. Dauletbayevna, T. K. Nartbayevna, B. B. E. Nurlanovich, M. R. Abdurazakovna

{"title":"Liver manifestation associated with covid-19 (Literature review)","authors":"S. A. Joya, K. G. Medeubaevna, S. Dauletbayevna, T. K. Nartbayevna, B. B. E. Nurlanovich, M. R. Abdurazakovna","doi":"10.5281/zenodo.5110307","DOIUrl":null,"url":null,"abstract":"he World Health Organization (WHO) named the 2019-nCoV virus on January 12, 2020 [1]. Subsequently, in a short period of time, Novel Coronavirus Infected Pneumonia (NCIP) spread around the world, and on January 30, 2020, the WHO declared NCIP an international public health emergency [2]. On February 11, 2020, it was renamed Coronavirus Disease 2019 (COVID-19) [3]. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which has been described as a form of the beta coronavirus cluster, is the cause of the pandemic and has 79.6% sequence identity with SARS-CoV [4]. COVID-19 is generally a self-limiting disease, but it can also be fa-tal: China’s death rate is around 2.3 percent [5], from 5.8 percent in Wuhan to 0.7 percent in the rest of China [6]. The proportion of serious or fatal infections that can be attributed to specific infected populations may vary by country and region. A certain percentage of deaths oc-curred in elderly patients or comorbid conditions (obesity, hypertension, diabetes, cardiovascular disease, chronic lung disease and cancer) [5;7;8]. These results were also found in critically ill patients re-ferred to the intensive care unit, indicating that adequate liver oxygen supply is provided by compensatory mecha-nisms, including in cases of severe respiratory failure during COVID-19 disease [9;10;11;12-17]. © 2021, Venezuelan Society of Pharmacology and Clinical and Therapeutic Pharmacology. All rights reserved.","PeriodicalId":49606,"journal":{"name":"Revista Latinoamericana De Hipertension","volume":"15 1","pages":"64-76"},"PeriodicalIF":0.1000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Latinoamericana De Hipertension","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.5110307","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

he World Health Organization (WHO) named the 2019-nCoV virus on January 12, 2020 [1]. Subsequently, in a short period of time, Novel Coronavirus Infected Pneumonia (NCIP) spread around the world, and on January 30, 2020, the WHO declared NCIP an international public health emergency [2]. On February 11, 2020, it was renamed Coronavirus Disease 2019 (COVID-19) [3]. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which has been described as a form of the beta coronavirus cluster, is the cause of the pandemic and has 79.6% sequence identity with SARS-CoV [4]. COVID-19 is generally a self-limiting disease, but it can also be fa-tal: China’s death rate is around 2.3 percent [5], from 5.8 percent in Wuhan to 0.7 percent in the rest of China [6]. The proportion of serious or fatal infections that can be attributed to specific infected populations may vary by country and region. A certain percentage of deaths oc-curred in elderly patients or comorbid conditions (obesity, hypertension, diabetes, cardiovascular disease, chronic lung disease and cancer) [5;7;8]. These results were also found in critically ill patients re-ferred to the intensive care unit, indicating that adequate liver oxygen supply is provided by compensatory mecha-nisms, including in cases of severe respiratory failure during COVID-19 disease [9;10;11;12-17]. © 2021, Venezuelan Society of Pharmacology and Clinical and Therapeutic Pharmacology. All rights reserved.

查看原文本刊更多论文

与covid-19相关的肝脏表现(文献复习)

世界卫生组织(世卫组织)于2020年1月12日将2019-nCoV命名为b[1]。随后，在短时间内，新型冠状病毒感染的肺炎(NCIP)在全球蔓延，世界卫生组织于2020年1月30日宣布NCIP为国际突发公共卫生事件。2020年2月11日，更名为2019冠状病毒病(COVID-19)[3]。严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)被描述为β冠状病毒簇的一种形式，是大流行的原因，与SARS-CoV[4]具有79.6%的序列一致性。COVID-19通常是一种自限性疾病，但它也可能是致命的:中国的死亡率约为2.3%，从武汉的5.8%到中国其他地区的0.7%。可归因于特定受感染人群的严重或致命感染的比例可能因国家和区域而异。一定比例的死亡发生在老年患者或合并症(肥胖、高血压、糖尿病、心血管疾病、慢性肺部疾病和癌症)中[5;7;8]。在转至重症监护室的危重患者中也发现了这些结果，表明补偿机制提供了充足的肝氧供应，包括COVID-19疾病期间严重呼吸衰竭的病例[9;10;11;12-17]。©2021，委内瑞拉药理学和临床与治疗药理学学会。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Latinoamericana De Hipertension 医学-外周血管病

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： La revista Latinoamericana de Hipertensión es una publicación biomédica periódica, arbitrada, de aparición trimestral, destinada a promover la productividad científica de la comunidad nacional e internacional en el área de Sistema Cardiovascular; así como todas aquellas publicaciones vinculadas a la medicina práctica en esta área. Su objetivo fundamental es la divulgación de artículos científicos y tecnológicos originales y artículos de revisión por invitación del Comité Editorial, asimismo, se admiten informes de investigaciones de corte cualitativo o cuantitativo; todos deben ser trabajos inéditos, no se hayan sometidos o hayan publicados en otra revista. El manuscrito debe ir acompañado de una carta solicitud firmada por el autor principal y el resto de los autores responsables del mismo. Está constituida por un Comité de redacción, organizado por Editor en Jefe, Editores Ejecutivos y Comité Editorial. Los manuscritos que publica pueden ser de autores nacionales o extranjeros, residentes o no en Venezuela, en castellano o en ingles (los resúmenes deben ser en ingles y castellano)